The benefit and risk of adding immunotherapy to chemoradiotherapy as the first-line treatment for limited-stage small cell lung cancer: a meta-analysis of randomized controlled trials
Xiang Fu, Yuanya Zhang, Yun Xu, Wenying Chen, Qingjian Hou, Wenxiong Zhang, Wen Zheng · 2025
Read The benefit and risk of adding immunotherapy to chemoradiotherapy as the first-line treatment for limited-stage small cell lung cancer: a meta-analysis of randomized controlled trials by Xiang Fu, Yuanya Zhang, Yun Xu, Wenying Chen, Qingjian Hou, Wenxiong Zhang, Wen Zheng (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12817411.txt.
Description
Xiang Fu and co-authors pool a 2025 set of trials on adding immune therapy to chemo and radiation for early-stage small cell lung cancer. The cancer is fierce and long survival is rare on standard care. Six trials with more than a thousand patients fed the tally, drawn from six databases.
The added immune drugs raised both total survival and time without growth, by set margins. Fast restart after chemo and one platinum type marked who gained most. Harm rates were pooled as well, so the gain can be weighed against the risk in first-line care.
Catalog record
| CREATOR | Xiang Fu, Yuanya Zhang, Yun Xu, Wenying Chen, Qingjian Hou, Wenxiong Zhang, Wen Zheng |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 42 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |